

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF TECHNOLOGY OFFICER

This announcement is made by Alphamab Oncology (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce the appointment of Dr. WANG Hongwei (王宏偉) (“**Dr. Wang**”) as the chief technology officer of our Company. Dr. Wang will be primarily responsible for the Company’s process development and analytical development, production, and quality.

The biographical details of Dr. Wang are set out below:

Dr. Wang has extensive experience in the CMC (Chemistry, Manufacturing, and Controls) development and commercial manufacturing management of biopharmaceuticals. He possesses deep expertise in managing the full lifecycle of biologics development, including biopharmaceutical development, technology transfer, regulatory registration and commercial production. Dr. Wang has led the successful approval and commercialization of six innovative biologic drugs and has advanced more than 20 product candidates into pivotal clinical stages.

Dr. Wang began his career at Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (SHSE: 600276; HKEX: 1276) (“**Hengrui Pharmaceuticals**”). From July 2011 to July 2018, he successively served as senior researcher, deputy director of research and development, deputy director of the Institute of Biologics and director of the Institute of Biologics of Hengrui Pharmaceuticals. From August 2018 to January 2026, Dr. Wang served successively as deputy general manager and general manager of Suzhou Suncadia Biopharmaceuticals Co., Ltd. (蘇州盛迪亞生物醫藥有限公司), a wholly-owned subsidiary of Hengrui Pharmaceuticals. From May 2023 to January 2026, Dr. Wang additionally served as general manager of the biopharmaceutical division of Hengrui Pharmaceuticals, where he was primarily responsible for coordinating biologics development and manufacturing operations.

Dr. Wang obtained a bachelor’s degree in bioscience from Henan Normal University (河南師範大學) in July 2006 and obtained a Ph.D. in cell biology (immunology) from University of Science and Technology of China (中國科學技術大學) in July 2011. He is also a member of the expert panel of the Ministry of Science and Technology of the PRC and an expert in the pharmaceutical industry field of the Ministry of Industry and Information Technology of the PRC.

The Board would like to express its warmest welcome to Dr. Wang.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, March 11, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.